Hochschulschrift
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
- Alternative title
-
Die Rolle DREAM/MMB-vermittelter mitotischer Genexpression unterhalb von mutiertem K-Ras in Lungenkrebs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Würzburg, Universität Würzburg, Dissertation, 2017
- Keyword
-
Nicht-kleinzelliges Bronchialkarzinom (NSCLC)
Lungenkrebs
Mitose
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2017
- Creator
- Contributor
-
Gaubatz, Stefan
Paeschke, Katrin
Murphy, Daniel J.
- URN
-
urn:nbn:de:bvb:20-opus-154108
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Iltzsche, Fabian
- Gaubatz, Stefan
- Paeschke, Katrin
- Murphy, Daniel J.
- Universität Würzburg
Time of origin
- 2017
Other Objects (12)
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer : = Die Rolle DREAM/MMB-vermittelter mitotischer Genexpression unterhalb von mutiertem K-Ras in Lungenkrebs
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer : = Die Rolle DREAM/MMB-vermittelter mitotischer Genexpression unterhalb von mutiertem K-Ras in Lungenkrebs
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer : = Die Rolle DREAM/MMB-vermittelter mitotischer Genexpression unterhalb von mutiertem K-Ras in Lungenkrebs
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma